Jul. 31 at 12:50 PM
$SUPN completes acquisition of
$SAGE
https://ir.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-completes-acquisition-sage-therapeutics
SAGE shareholders receive
$8.50 per share plus a CVR per share. CVR can pay out a max of
$3.50:
1) One milestone payment of
$0.50 per CVR upon the first commercial sale after Regulatory Approval in Japan for ZURZUVAE for Major Depressive Disorder by June 30, 2026.
2)
$1.00 per CVR if U.S. Net Sales of ZURZUVAE are equal to or exceed
$250M during a calendar year on or prior to December 31, 2027.
3)
$1.00 per CVR if U.S. Net Sales of ZURZUVAE are equal to or exceed
$300 million during a calendar year on or prior to December 31, 2028.
4)
$1.00 per CVR if U.S. Net Sales of ZURZUVAE are equal to or exceed
$375 million during a calendar year on or prior to December 31, 2030.
